Session Information
Date: Thursday, June 23, 2016
Session Title: Other
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To prepare and evaluate the nanoherbaceutical formulation containing natural L-DOPA from Mucuna pruriens against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced Parkinson’s disease (PD).
Background: PD is the most prevalent neurodegenerative disorder after Alzheimer’s disease. The loss of dopamenergic neurons in brain results in the lower level of dopamine in the brain regions like Subtantia nigra which ultimately leads to the development of PD. Mucuna pruriens a rich source of natural 3-(3,4-dihydroxyphenyl)-l-alanine (L-DOPA) along with other ingredient has shown a very promising anti Parkinson activity without showing any untoward effect.
Methods: In the present study, we have prepared the nanoherbaceutical suspension by using top-down technique. Drug release from the prepared nanoherbaceutical was found to be much faster as compared with the microsuspension of aquous extract. We used the MPTP to induce the PD. We confirmed that the MPTP altered the behavioral deficits, diminution of dopamine and its metabolites, reduction in glutathione (GSH), superoxide dismutase (SOD), glutathione peroxidase (GPx) activity and the enhanced level of malondialdehyde (MDA) levels in the substantia nigra.
Results: After nanoherbaceutical treatment an increase in levodopa level was observed in the treatment group (79 pmol/mg proteins) as compared to toxic group (21 pmol/mg protein). Significant reduction in nitrite level and lipid peroxidation was observed in the experimental groups. In behavior assessment test the treatment groups had shown a decrease in the time to cross the narrow path in the drum platform and increase in the time of stay in the platform. Nanoherbaceutical increased the GSH, SOD and GPx activity and decreased the MDA level as compared to the MPTP control group animals.
Conclusions: It may be concluded that the nanoherbaceutical preparation of mucuna pruriens should be considered as an alternative to the current therapies as it can serve as an effective and safe measure in case of Parkinson’s disease by acting as a natural neurorestorative and neuroprotective.
To cite this abstract in AMA style:
P.C. Bhatt, V. Kumar. Development of a nanoherbaceutical containing natural L-DOPA from mucuna pruriens for the prevention and treatment of Parkinson’s disease in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced animal model [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/development-of-a-nanoherbaceutical-containing-natural-l-dopa-from-mucuna-pruriens-for-the-prevention-and-treatment-of-parkinsons-disease-in-1-methyl-4-phenyl-1236-tetrahydropyridine-induced-animal/. Accessed June 14, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/development-of-a-nanoherbaceutical-containing-natural-l-dopa-from-mucuna-pruriens-for-the-prevention-and-treatment-of-parkinsons-disease-in-1-methyl-4-phenyl-1236-tetrahydropyridine-induced-animal/